140 related articles for article (PubMed ID: 24056893)
1. Is there a role for bevacizumab in the treatment of glioblastoma?
Chi AS; Chamberlain MC
Oncologist; 2013; 18(10):1080-2. PubMed ID: 24056893
[TBL] [Abstract][Full Text] [Related]
2. High-dose antiangiogenic therapy for glioblastoma: less may be more?
de Groot JF
Clin Cancer Res; 2011 Oct; 17(19):6109-11. PubMed ID: 21852387
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab for acute neurologic deterioration in patients with glioblastoma.
Kaley T; Nolan C; Carver A; Omuro A
CNS Oncol; 2013 Sep; 2(5):413-8. PubMed ID: 25054664
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab and recurrent malignant gliomas: a European perspective.
Wick W; Weller M; van den Bent M; Stupp R
J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
[No Abstract] [Full Text] [Related]
5. Treatment of glioblastoma with bevacizumab: has a new standard therapy been defined?
Chamberlain MC
CNS Drugs; 2011 Oct; 25(10):815-8. PubMed ID: 21936584
[No Abstract] [Full Text] [Related]
6. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
7. Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma.
Wiestler B; Radbruch A; Osswald M; Combs SE; Jungk C; Winkler F; Bendszus M; Unterberg A; Platten M; Wick W; Wick A
J Neurooncol; 2014 Mar; 117(1):85-92. PubMed ID: 24458956
[TBL] [Abstract][Full Text] [Related]
8. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
9. Spinal cord metastasis in a patient treated with bevacizumab for glioblastoma.
Lomax AJ; Yannakou CK; Rosenthal MA
Target Oncol; 2013 Jun; 8(2):153-5. PubMed ID: 23430346
[TBL] [Abstract][Full Text] [Related]
10. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.
Pope WB; Lai A; Mehta R; Kim HJ; Qiao J; Young JR; Xue X; Goldin J; Brown MS; Nghiemphu PL; Tran A; Cloughesy TF
AJNR Am J Neuroradiol; 2011 May; 32(5):882-9. PubMed ID: 21330401
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in glioblastoma multiforme.
Specenier P
Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF
AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647
[TBL] [Abstract][Full Text] [Related]
13. Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?
Desjardins A
Nat Rev Neurol; 2015 Aug; 11(8):429-30. PubMed ID: 26195258
[No Abstract] [Full Text] [Related]
14. First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?
Marosi C
CNS Oncol; 2013 Nov; 2(6):473-4. PubMed ID: 25054815
[No Abstract] [Full Text] [Related]
15. [An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].
Dehais C; Souvannavong V; Nguyen BK; Jouniaux-Delbez N; Golmard JL; Tadrist C; Liou A; Delattre JY
Rev Neurol (Paris); 2011 Nov; 167(11):841-6. PubMed ID: 21514945
[TBL] [Abstract][Full Text] [Related]
16. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
[TBL] [Abstract][Full Text] [Related]
17. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Kovic B; Xie F
J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
Reardon DA; Herndon JE; Peters KB; Desjardins A; Coan A; Lou E; Sumrall AL; Turner S; Lipp ES; Sathornsumetee S; Rich JN; Sampson JH; Friedman AH; Boulton ST; Bigner DD; Friedman HS; Vredenburgh JJ
Br J Cancer; 2012 Oct; 107(9):1481-7. PubMed ID: 23037712
[TBL] [Abstract][Full Text] [Related]
19. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.
Piccioni DE; Selfridge J; Mody RR; Chowdhury R; Li S; Lalezari S; Wawrzynski J; Quan J; Zurayk M; Chou AP; Sanchez DE; Liau LM; Ellingson BM; Pope WB; Nghiemphu PL; Green RM; Wang HJ; Yong WH; Elashoff R; Cloughesy TF; Lai A
Neuro Oncol; 2014 Jun; 16(6):815-22. PubMed ID: 24627236
[TBL] [Abstract][Full Text] [Related]
20. Disseminated progression of glioblastoma after treatment with bevacizumab.
Bloch O; Safaee M; Sun MZ; Butowski NA; McDermott MW; Berger MS; Aghi MK; Parsa AT
Clin Neurol Neurosurg; 2013 Sep; 115(9):1795-801. PubMed ID: 23706614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
